This approach of targeting cytokines to enhance their activity against cancer cells is a novel approach to help augment IL-27′s bioactivity and efficacy against prostate tumors, and could be extended to other conditions where it could help interfere with the eIF2α pathway and promote caspase-3 activation. This evidence concerns the gene CASP3 and prostate neoplasm.